Carolina Cimminiello

Milan, 20141, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 27 publications

Adjuvant Approaches in Fully Resected Stage III and IV Cutaneous Melanoma: Where Are We Now?

Adjuvant Approaches in Fully Resected Stage III and IV Cutaneous Melanoma: Where Are We Now?

Journal: Cancers

Published: May 04, 2026

Adjuvant Therapy for High-Risk Stage II Cutaneous Melanoma: Insights and Future Directions.

Adjuvant Therapy for High-Risk Stage II Cutaneous Melanoma: Insights and Future Directions.

Journal: Cancers

Published: April 16, 2026

Neoadjuvant Therapy and the Evolving Management of Resectable Advanced Melanoma.

Neoadjuvant Therapy and the Evolving Management of Resectable Advanced Melanoma.

Journal: Cancers

Published: April 14, 2026

New Perspectives and Open Issues in the Adjuvant and Neoadjuvant Treatment of Melanoma.

New Perspectives and Open Issues in the Adjuvant and Neoadjuvant Treatment of Melanoma.

Journal: Cancers

Published: April 14, 2026

MONETTE: A Randomized Phase II Study of Ceralasertib plus Durvalumab or Ceralasertib Monotherapy in Patients with Advanced Melanoma Resistant to PD-(L)1 Inhibition.

MONETTE: A Randomized Phase II Study of Ceralasertib plus Durvalumab or Ceralasertib Monotherapy in Patients with Advanced Melanoma Resistant to PD-(L)1 Inhibition.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: November 06, 2025

Sex and gender influence on adverse events for melanoma patients: a comprehensive review and meta-analysis.

Sex and gender influence on adverse events for melanoma patients: a comprehensive review and meta-analysis.

Journal: British journal of cancer

Published: June 17, 2025

Fertility preservation for patients with melanoma.

Fertility preservation for patients with melanoma.

Journal: Melanoma research

Published: July 20, 2022

The Pan-Immune-Inflammation Value in Patients with Metastatic Melanoma Receiving First-Line Therapy.

The Pan-Immune-Inflammation Value in Patients with Metastatic Melanoma Receiving First-Line Therapy.

Journal: Targeted oncology

Published: May 16, 2021

Characterization and management of neurological adverse events during immune-checkpoint inhibitors treatment: an Italian multicentric experience.

Characterization and management of neurological adverse events during immune-checkpoint inhibitors treatment: an Italian multicentric experience.

Journal: Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology

Published: April 06, 2021

Liquid Biopsy and Radiological Response Predict Outcomes Following Discontinuation of Targeted Therapy in Patients with BRAF Mutated Melanoma.

Liquid Biopsy and Radiological Response Predict Outcomes Following Discontinuation of Targeted Therapy in Patients with BRAF Mutated Melanoma.

Journal: The oncologist

Published: April 01, 2021

Immune-related Bell's palsy in melanoma patients treated with immune checkpoint inhibitors.

Immune-related Bell's palsy in melanoma patients treated with immune checkpoint inhibitors.

Journal: Melanoma research

Published: January 25, 2021

Survival in Patients With Sentinel Node-Positive Melanoma With Extranodal Extension.

Survival in Patients With Sentinel Node-Positive Melanoma With Extranodal Extension.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: July 09, 2020

Showing 1-12 of 27

Last Updated: 09/26/2026